ArticleFrontiers in neuroscience2017
NPY1 Receptor Agonist Modulates Development of Depressive-Like Behavior and Gene Expression in Hypothalamus in SPS Rodent PTSD Model.
Article in Frontiers in neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- Neuropeptide Y and Pain: Insights from Brain Research.ACS pharmacology & translational science · 2024Review
- Article
- GALR2 and Y1R agonists intranasal infusion enhanced adult ventral hippocampal neurogenesis and antidepressant-like effects involving BDNF actions.Journal of cellular physiology · 2023Article
- Functional Neuroimaging in Dissociative Disorders: A Systematic Review.Journal of personalized medicine · 2022Review
- Intranasal Delivery of Galanin 2 and Neuropeptide Y1 Agonists Enhanced Spatial Memory Performance and Neuronal Precursor Cells Proliferation in the Dorsal Hippocampus in Rats.Frontiers in pharmacology · 2022Article
- Intranasal neuropeptide Y is most effective in some aspects of acute stress compared to melatonin, oxytocin and orexin.Frontiers in pharmacology · 2022Article
- Sex Differences in the Neuropeptide Y System and Implications for Stress Related Disorders.Biomolecules · 2020Review
- Cannabidiol improves survival and behavioural co-morbidities of Dravet syndrome in mice.British journal of pharmacology · 2020Article
- No Association of Variants of the NPY-System With Obsessive-Compulsive Disorder in Children and Adolescents.Frontiers in molecular neuroscience · 2019Article
- Single Prolonged Stress as a Prospective Model for Posttraumatic Stress Disorder in Females.Frontiers in behavioral neuroscience · 2019Article
- Differential effects of chronic stress in young-adult and old female mice: cognitive-behavioral manifestations and neurobiological correlates.Molecular psychiatry · 2018Article
- Neuropeptide Y in Alcohol Addiction and Affective Disorders.Frontiers in endocrinology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delivery of neuropeptide Y (NPY) to the brain by intranasal infusion soon after traumatic stress has shown therapeutic potential, and prevented development of many behavioral and neuroendocrine impairments in the single prolonged stress (SPS) animal model of PTSD. Therefore, we examined whether the Y1R preferring agonist [Leu
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.